Media Coverage: Small Cap Idea profile

In brief · summary, not quotable

Media coverage published highlighting company's acquisition of Awakn Life Sciences and clinical development programmes.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes

Media Coverage: Small Cap Idea profile in ThisIsMoney.co.uk / Daily Mail.

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, notes the publication of an article on ThisIsMoney.co.uk (Daily Mail online) titled "SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism".

The article, written by Ian Lyall of Proactive Investors, highlights:

Solvonis' recent acquisition of Awakn Life Sciences and the integration of its development pipeline.
The Company's lead programme, SVN-001, in Phase III clinical trials for severe AUD for the UK and EU AUD markets, combining ketamine infusion with Cognitive Behavioural Therapy (CBT).
The Company's second programme, SVN-002, targeting the US AUD market via the FDA's 505(b)(2) regulatory pathway, referencing Johnson & Johnson's approved esketamine product Spravato®.
Sector valuation comparisons with US-listed peers and recent M&A activity highlighting strategic interest in novel mental health therapeutics.
The full article can be accessed here:

solvonis.com

X (Twitter)

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.